Osaic Holdings’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-150
| Closed | -$2.24K | – | 7912 |
|
|
2025
Q2 | $2.24K | Sell |
150
-617
| -80% | -$5.64K | ﹤0.01% | 6896 |
|
|
2025
Q1 | $7.24K | Sell |
767
-230
| -23% | -$2.68K | ﹤0.01% | 5962 |
|
|
2024
Q4 | $12.3K | Buy |
997
+786
| +373% | +$11.1K | ﹤0.01% | 5650 |
|
|
2024
Q3 | $3.15K | Hold |
211
| – | – | ﹤0.01% | 6412 |
|
|
2024
Q2 | $2.85K | Sell |
211
-65
| -24% | -$962 | ﹤0.01% | 6457 |
|
|
2024
Q1 | $4.59K | Buy |
276
+126
| +84% | +$1.94K | ﹤0.01% | 6125 |
|
|
2023
Q4 | $2.02K | Sell |
150
-3,485
| -96% | -$38.1K | ﹤0.01% | 6543 |
|
|
2023
Q3 | $39.8K | Buy |
3,635
+150
| +4% | +$1.83K | ﹤0.01% | 5150 |
|
|
2023
Q2 | $45K | Sell |
3,485
-300
| -8% | -$3.93K | ﹤0.01% | 5005 |
|
|
2023
Q1 | $45.4K | Sell |
3,785
-36
| -0.9% | -$491 | ﹤0.01% | 5018 |
|
|
2022
Q4 | $52.6K | Buy |
3,821
+3,321
| +664% | +$48.6K | ﹤0.01% | 4895 |
|
|
2022
Q3 | $7K | Hold |
500
| – | – | ﹤0.01% | 6173 |
|
|
2022
Q2 | $8K | Sell |
500
-2,294
| -82% | -$35.2K | ﹤0.01% | 6222 |
|
|
2022
Q1 | $50K | Buy |
2,794
+1,326
| +90% | +$25.2K | ﹤0.01% | 5088 |
|
|
2021
Q4 | $35K | Sell |
1,468
-182
| -11% | -$5.06K | ﹤0.01% | 5408 |
|
|
2021
Q3 | $50K | Sell |
1,650
-10
| -0.6% | -$302 | ﹤0.01% | 5098 |
|
|
2021
Q2 | $53K | Buy |
1,660
+10
| +0.6% | +$302 | ﹤0.01% | 4998 |
|
|
2021
Q1 | $50K | Buy |
1,650
+508
| +44% | +$16.5K | ﹤0.01% | 4880 |
|
|
2020
Q4 | $37K | Sell |
1,142
-67
| -6% | -$2.01K | ﹤0.01% | 4767 |
|
|
2020
Q3 | $34K | Sell |
1,209
-239
| -17% | -$6.39K | ﹤0.01% | 4573 |
|
|
2020
Q2 | $40K | Buy |
1,448
+59
| +4% | +$1.45K | ﹤0.01% | 4345 |
|
|
2020
Q1 | $28K | Buy |
+1,389
| New | +$29.9K | ﹤0.01% | 4410 |
|
Osaic Holdings's CNCR Position: Q3 2025 in Review
Osaic Holdings sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2025, closing a stake of 150 shares — an estimated $2.24K sold.
Osaic Holdings first reported a position in CNCR in Q1 2020 and held it in 22 quarters. The position peaked at $53K in Q2 2021. 0 funds tracked by Wall St. Rank hold CNCR as of Q3 2025.
- Osaic Holdings reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2025 after selling out during the quarter.
- Osaic Holdings sold 150 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2025, an estimated $2.24K.
- Osaic Holdings first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2020 and held it in 22 quarters.
- Osaic Holdings's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $53K in Q2 2021.
- 0 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2025.
Based on Osaic Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.